| Not Yet Recruiting | SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Urothelial Carcinoma | Phase 3 | 2026-06-20 |
| Not Yet Recruiting | SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma Advanced Urothelial Carcinoma | Phase 2 | 2026-06-20 |
| Not Yet Recruiting | A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breas Recurrent or Metastatic Breast Cancer | Phase 3 | 2026-04-01 |
| Not Yet Recruiting | SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma Locally Advanced/Metastatic/Recurrent ESCC | Phase 3 | 2026-03-18 |
| Not Yet Recruiting | SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ Non-Small Cell Lung Cancer | Phase 3 | 2026-03-10 |
| Not Yet Recruiting | A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metas NSCLC | Phase 3 | 2026-03-03 |
| Not Yet Recruiting | Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above Herpes Zoster | Phase 2 | 2026-01-10 |
| Not Yet Recruiting | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcin Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | 2025-12-30 |
| Recruiting | SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma | Phase 2 | 2025-12-18 |
| Not Yet Recruiting | A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With Non-Small Cell Lung Cancer | Phase 2 | 2025-11-30 |
| Not Yet Recruiting | SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Cervical Cancer | Phase 3 | 2025-11-20 |
| Not Yet Recruiting | SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC Head and Neck Squamous Cell Carcinoma | Phase 2 | 2025-08-30 |
| Active Not Recruiting | Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Pati Advanced Solid Tumors | Phase 1 / Phase 2 | 2025-08-11 |
| Not Yet Recruiting | Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More Herpes Zoster | Phase 1 | 2025-05-10 |
| Recruiting | A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors Small Cell Lung Cancer, Other Advanced Solid Tumors | Phase 1 | 2025-04-10 |
| Recruiting | Evaluation of SYS6005 in Patients With Advanced Malignant Tumor B-cell Malignancies, Solid Tumors | Phase 1 | 2025-04-03 |
| Recruiting | Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） EGFR-mutated Locally Advanced or Metastatic NSCLC | Phase 3 | 2025-03-30 |
| Not Yet Recruiting | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors Advanced Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | 2025-03-20 |
| Recruiting | Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors Advanced/Metastatic Solid Tumors | Phase 1 / Phase 2 | 2024-12-30 |
| Recruiting | A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2024-08-15 |